Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Savonix has raised $5.1m to further advance its mobile app-based cognitive assessment tool used by clinicians to help develop their patients' treatment plan. The company's founder and CEO, Mylea Charvat, said the 30-minute assessment is faster and much more cost-effective than conventional paper and pen testing, and opens the door for better outcomes for patients who otherwise wouldn't have access to cognitive testing.

Prolacta Bioscience developed human milk-based formula fortifier for full-term infants born with conditions that make them vulnerable to nutrition deficiencies. Pending results from research at 12 US hospitals, the product would roll out commercially in 2018.